Large-scale validation of skin prion seeding activity as a biomarker for diagnosis of prion diseases
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature..
Definitive diagnosis of sporadic Creutzfeldt-Jakob disease (sCJD) relies on the examination of brain tissues for the pathological prion protein (PrPSc). Our previous study revealed that PrPSc-seeding activity (PrPSc-SA) is detectable in skin of sCJD patients by an ultrasensitive PrPSc seed amplification assay (PrPSc-SAA) known as real-time quaking-induced conversion (RT-QuIC). A total of 875 skin samples were collected from 2 cohorts (1 and 2) at autopsy from 2-3 body areas of 339 cases with neuropathologically confirmed prion diseases and non-sCJD controls. The skin samples were analyzed for PrPSc-SA by RT-QuIC assay. The results were compared with demographic information, clinical manifestations, cerebrospinal fluid (CSF) PrPSc-SA, other laboratory tests, subtypes of prion diseases defined by the methionine (M) or valine (V) polymorphism at residue 129 of PrP, PrPSc types (#1 or #2), and gene mutations in deceased patients. RT-QuIC assays of the cohort #1 by two independent laboratories gave 87.3% or 91.3% sensitivity and 94.7% or 100% specificity, respectively. The cohort #2 showed sensitivity of 89.4% and specificity of 95.5%. RT-QuIC of CSF available from 212 cases gave 89.7% sensitivity and 94.1% specificity. The sensitivity of skin RT-QuIC was subtype dependent, being highest in sCJDVV1-2 subtype, followed by VV2, MV1-2, MV1, MV2, MM1, MM1-2, MM2, and VV1. The skin area next to the ear gave highest sensitivity, followed by lower back and apex of the head. Although no difference in brain PrPSc-SA was detected between the cases with false negative and true positive skin RT-QuIC results, the disease duration was significantly longer with the false negatives [12.0 ± 13.3 (months, SD) vs. 6.5 ± 6.4, p < 0.001]. Our study validates skin PrPSc-SA as a biomarker for the detection of prion diseases, which is influenced by the PrPSc types, PRNP 129 polymorphisms, dermatome sampled, and disease duration.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:147 |
|---|---|
| Enthalten in: |
Acta neuropathologica - 147(2024), 1 vom: 17. Jan., Seite 17 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Weiguanliu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarker |
|---|
| Anmerkungen: |
Date Completed 18.01.2024 Date Revised 18.01.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00401-023-02661-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367218259 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367218259 | ||
| 003 | DE-627 | ||
| 005 | 20240118232149.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240117s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00401-023-02661-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1263.xml |
| 035 | |a (DE-627)NLM367218259 | ||
| 035 | |a (NLM)38231266 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, Weiguanliu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Large-scale validation of skin prion seeding activity as a biomarker for diagnosis of prion diseases |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.01.2024 | ||
| 500 | |a Date Revised 18.01.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. | ||
| 520 | |a Definitive diagnosis of sporadic Creutzfeldt-Jakob disease (sCJD) relies on the examination of brain tissues for the pathological prion protein (PrPSc). Our previous study revealed that PrPSc-seeding activity (PrPSc-SA) is detectable in skin of sCJD patients by an ultrasensitive PrPSc seed amplification assay (PrPSc-SAA) known as real-time quaking-induced conversion (RT-QuIC). A total of 875 skin samples were collected from 2 cohorts (1 and 2) at autopsy from 2-3 body areas of 339 cases with neuropathologically confirmed prion diseases and non-sCJD controls. The skin samples were analyzed for PrPSc-SA by RT-QuIC assay. The results were compared with demographic information, clinical manifestations, cerebrospinal fluid (CSF) PrPSc-SA, other laboratory tests, subtypes of prion diseases defined by the methionine (M) or valine (V) polymorphism at residue 129 of PrP, PrPSc types (#1 or #2), and gene mutations in deceased patients. RT-QuIC assays of the cohort #1 by two independent laboratories gave 87.3% or 91.3% sensitivity and 94.7% or 100% specificity, respectively. The cohort #2 showed sensitivity of 89.4% and specificity of 95.5%. RT-QuIC of CSF available from 212 cases gave 89.7% sensitivity and 94.1% specificity. The sensitivity of skin RT-QuIC was subtype dependent, being highest in sCJDVV1-2 subtype, followed by VV2, MV1-2, MV1, MV2, MM1, MM1-2, MM2, and VV1. The skin area next to the ear gave highest sensitivity, followed by lower back and apex of the head. Although no difference in brain PrPSc-SA was detected between the cases with false negative and true positive skin RT-QuIC results, the disease duration was significantly longer with the false negatives [12.0 ± 13.3 (months, SD) vs. 6.5 ± 6.4, p < 0.001]. Our study validates skin PrPSc-SA as a biomarker for the detection of prion diseases, which is influenced by the PrPSc types, PRNP 129 polymorphisms, dermatome sampled, and disease duration | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Biomarker | |
| 650 | 4 | |a Prion | |
| 650 | 4 | |a Protein misfolding cyclic amplification (PMCA) | |
| 650 | 4 | |a Real-time quaking-induced conversion (RT-QuIC) | |
| 650 | 4 | |a Seeding activity | |
| 650 | 4 | |a Skin | |
| 650 | 7 | |a Prions |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Orrú, Christina D |e verfasserin |4 aut | |
| 700 | 1 | |a Foutz, Aaron |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Mingxuan |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Jue |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Syed Zahid Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Kotobelli, Keisi |e verfasserin |4 aut | |
| 700 | 1 | |a Gerasimenko, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Gilliland, Tricia |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Michelle |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Safar, Jiri |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Hong, Dao-Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Cui, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Hughson, Andrew G |e verfasserin |4 aut | |
| 700 | 1 | |a Schonberger, Lawrence B |e verfasserin |4 aut | |
| 700 | 1 | |a Tatsuoka, Curtis |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Shu G |e verfasserin |4 aut | |
| 700 | 1 | |a Greenlee, Justin J |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Zerui |e verfasserin |4 aut | |
| 700 | 1 | |a Appleby, Brian S |e verfasserin |4 aut | |
| 700 | 1 | |a Caughey, Byron |e verfasserin |4 aut | |
| 700 | 1 | |a Zou, Wen-Quan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Acta neuropathologica |d 1961 |g 147(2024), 1 vom: 17. Jan., Seite 17 |w (DE-627)NLM000036641 |x 1432-0533 |7 nnns |
| 773 | 1 | 8 | |g volume:147 |g year:2024 |g number:1 |g day:17 |g month:01 |g pages:17 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00401-023-02661-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 147 |j 2024 |e 1 |b 17 |c 01 |h 17 | ||